Business Wire

TX-FLUENCE

21.9.2022 15:11:14 CEST | Business Wire | Press release

Share
Fluence VYPR Selected as Supplemental Lighting Solution for Wageningen University & Research Facility, NPEC

Fluence, a leading global provider of energy-efficient LED lighting solutions for commercial cannabis and food production, has been selected by Wageningen University & Research (WUR) as the LED technology partner for its new Netherlands Plant Eco-phenotyping Centre (NPEC). In NPEC’s state-of-the-art phenotyping greenhouse, VYPR DUO 3x2 fixtures are used to support research on genotype-phenotype associations.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220921005421/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

In NPEC’s state-of-the-art phenotyping greenhouse, VYPR DUO 3x2 fixtures are used to support research on genotype-phenotype associations. (Photo: Business Wire)

The official opening of NPEC will take place preceding the weeklong International Plant Phenotyping Symposium 2022 (IPPS 2022), held from Sept. 26 to Sept. 30 in Wageningen, Netherlands. Fluence, a Gold Sponsor of IPPS 2022, will attend the conference and opening of NPEC in Wageningen.

NPEC consists of six modules across two university campuses, each offering dedicated phenotyping platforms with its own measurement systems. A specialized greenhouse at the WUR campus houses five climate-controlled compartments outfitted with Fluence’s VYPR DUO 3x2 fixtures. The compartments’ 3D and hyperspectral imaging, conveyor systems and various sensors produce high-precision measurements—including plant size, color and leaf positioning—that can be examined to understand the genetic response of plants to varied conditions and treatments, such as heat, drought or increased soil salinification.

“Using highly customizable technologies that generate high-quality plant performance data on how environmental parameters affect the plant phenotype was a key requirement when selecting our equipment partners,” said Rick van de Zedde, senior scientist and project manager for NPEC. “Having worked with Fluence for the lighting in our Serre Red high-tech quarantine greenhouse, we knew PhysioSpec™️ BROAD R4 white spectrum fixtures could help establish a near-ideal research environment in the NPEC greenhouse.”

In addition to Fluence’s VYPR top lights, which feature PhysioSpec™️ BROAD R4 white spectrum, NPEC researchers will use the Maxi-MARVIN imaging cabinet to assist in research, a high-throughput 3D modeling system developed by WUR that can reconstruct a plant’s architecture within milliseconds. Other high-tech research tools at WUR include a dark and light adaptation chamber and imaging systems capability to analyze the photosynthetic efficiency of plants.

“Establishing research on genotype-phenotype associations, specifically how ecological and environmental variables impact the plant phenotype, is essential for the development of novel, climate-proof crops,” explained van de Zedde. “Automated phenotyping will also allow for a dramatic increase in the speed of plant breeding and time to market for novel crop varieties.”

“We are honored to partner with WUR to advance the future of high-quality food production and sustainability in cultivation,” said Theo Tekstra, Fluence’s technical director for Europe, the Middle East and Africa and team lead for the WUR project. “Our PhysioSpec™️ BROAD R4 white spectrum came closest to what the WUR scientific team defined as an ideal spectrum to do year-round research on a wide range of plant species.”

Fluence's continuing partnership with WUR also includes LED fixtures in a specialized greenhouse for insect research and phenotyping climate rooms at Wageningen. Read more about Fluence’s collaborations with WUR here.

For more information on Fluence, visit www.fluence.science.

About Fluence

Fluence Bioengineering, Inc. (Fluence) creates powerful and energy-efficient LED lighting solutions for commercial crop production and research applications. Fluence is a leading LED lighting supplier in the global cannabis market and is committed to enabling more efficient crop production with the world’s top vertical farms and greenhouse produce growers. Fluence global headquarters are in Austin, Texas, with its EMEA headquarters in Rotterdam, Netherlands. Fluence operates as a business unit within Signify’s Digital Solutions division. For more information about Fluence, visit www.fluence.science.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220921005421/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 15:00:00 CEST | Press release

Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around

Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release

Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5

HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release

HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate

Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro

Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release

Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye